PT  - JOURNAL ARTICLE
AU  - Schuler, James
AU  - Falls, Zackary
AU  - Mangione, William
AU  - Hudson, Matthew L.
AU  - Bruggemann, Liana
AU  - Samudrala, Ram
TI  - Evaluating Performance of Drug Repurposing Technologies
AID  - 10.1101/2020.12.03.410274
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.12.03.410274
4099  - http://biorxiv.org/content/early/2020/12/03/2020.12.03.410274.short
4100  - http://biorxiv.org/content/early/2020/12/03/2020.12.03.410274.full
AB  - Drug repurposing technologies are growing in number and maturing. However, comparison to each other and to reality is hindered due to lack of consensus with respect to performance evaluation. Such comparability is necessary to determine scientific merit and to ensure that only meaningful predictions from repurposing technologies carry through to further validation and eventual patient use. Here, we review and compare performance evaluation measures for these technologies using version 2 of our shotgun repurposing Computational Analysis of Novel Drug Opportunities (CANDO) platform to illustrate their benefits, drawbacks, and limitations. Understanding and using different performance evaluation metrics ensures robust cross platform comparability, enabling us to continuously strive towards optimal repurposing by decreasing time and cost of drug discovery and development.Competing Interest StatementThe authors have declared no competing interest.